HIVにおける持効性抗レトロウイルス薬および避妊薬の薬物動態研究 (PHARAOH)
HIV予防における持続性抗レトロウイルス薬と避妊選択肢の薬物動態研究
This study is being done to understand how long-acting injectable cabotegravir (CAB-LA) used for HIV pre-exposure prophylaxis (PrEP) and hormonal contraceptive methods affect each other when used at the same time. Women who are already using CAB-LA or not using PrEP will choose to join one of several groups based on whether they use injectable contraceptive (IM DMPA), an etonogestrel implant, or no hormonal contraceptive. Participants will have study visits every 4 to 12 weeks for up to 12 or 24 weeks after starting a contraceptive method to collect blood samples and measure levels of CAB-LA and hormone concentrations. The study will compare these levels to see if taking CAB-LA changes hormone concentrations or if using hormonal contraception changes CAB-LA drug levels. Safety, side effects, satisfaction, and continuation of CAB-LA PrEP and contraceptive methods will also be evaluated.
調査の概要
状態
詳細な説明
Long-acting (LA) HIV pre-exposure prophylaxis (PrEP), such as injectable cabotegravir (CAB-LA), is increasingly available and has the potential to address barriers to adherence seen with daily oral PrEP. LA PrEP regimens can expand options for women and providers to individualize prevention strategies, provide a powerful prevention tool for those facing adherence challenges with oral regimens, and reduce the burden on health systems in resource-limited settings. Another major threat to women's health is unintended pregnancies, and women at risk for HIV face unique challenges in uptake and continuation of long-acting contraceptives. Use of CAB-LA may create synergy with long-acting contraceptives, fostering more consistent uptake and improved health outcomes.
This proposed research study is a prospective, non-randomized, parallel-group pharmacokinetic (PK) study among a sentinel cohort of five distinct groups of AGYW, and will leverage existing control groups. The study will be conducted in Botswana.
This study will generate critical data to guide future implementation studies integrating CAB-LA PrEP and contraceptive services. Providing an array of prevention and reproductive health options has the potential to empower women to make informed decisions, improve adherence and continuation, and inform real-world considerations for co-delivery or future co-formulations of PrEP and contraceptives.
Our central hypotheses are the following:
- CAB-LA will not adversely influence hormonal contraceptive concentrations;
- Hormonal contraceptive method use will not adversely modify CAB-LA concentrations below therapeutically relevant plasma concentrations.
Primary Objectives:
- To evaluate any associations between CAB-LA exposure and hormonal contraceptive use in the three groups of IM DMPA, ETG implant, and non-hormonal method users by generating geometric mean hormone concentrations throughout 12 weeks for IM DMPA or 24 weeks for ETG implant and no hormonal method groups (Aim 1a)
- To evaluate any associations between hormonal contraceptive exposure and CAB-LA use by generating geometric mean trough CAB-LA concentrations measured immediately prior to dosing of next CAB-LA (Aim 1b)
Exploratory Objectives
- To assess safety, including side effects, satisfaction, and continuation rates of both LA ART/PrEP and hormonal contraceptive method (Aim 2a)
- To qualitatively explore decision-making around PrEP and contraceptive method options, study experiences with use of/switch to CAB-LA and contraceptive method (Aim 2b)
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Rena Patel, MD, MPH
- 電話番号:205.934.8145
- メール:renapatel@uabmc.edu
研究場所
-
-
Gaborone
-
Bontleng、Gaborone、ボツワナ
- 募集
- Princess Marina Hospital
-
コンタクト:
- Chelsea Morroni, MBChB, DFSRH, DTMH, MPhil, MPH
- 電話番号:+267 765 24112
- メール:cmorroni@ed.ac.uk
-
コンタクト:
- Bame Bame
- 電話番号:+267 72727347
- メール:bbame@bhp.org.bw
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Adult females aged 18 years or older who are HIV-seronegative
説明
Parent Tshireletso Study Inclusion Criteria:
- Female 18 years of age or older and willing and able to provide an informed consent
- < 14 days after delivery (calendar day of birth = day 0)
- Negative HIV screening test (conducted at the time of enrolment)
- Female <30 years old or has had < 3 prior pregnancies (Gravida 1, 2, or 3 including this pregnancy)
- Plan to stay and receive postpartum and pediatric care in the Gaborone or Molepolole region for 24 months
Parent Tshireletso Study Exclusion Criteria
- Receiving carbamazepine, phenobarbital, phenytoin, oxycarbazepine, rifampin, rifabutin, rifapentine, systemic dexamethasone (>1 dose oral/IV), or St. John's wort
- Suspected to have, recently diagnosed with, or on treatment for TB (due to interaction with rifampicin)
- Previous hypersensitivity reaction to CAB or other INSTI
- Unstable medical or psychiatric condition making it unlikely they will be able to adhere to injections every 2 months
- Plan for pediatric and post-partum care outside the government system (private clinics)
- Inflammatory skin condition that compromises the safety of the intramuscular injection
- Weight <35kg
Parent Doris Duke Study Inclusion Criteria Post-partum females included;
- if HIV-uninfected or unknown HIV status, willing to be tested for HIV
- if HIV-infected, documented to be on DTG as part of an antiretroviral treatment regimen
- maternal age >18 years,
- ability to speak English or Setswana
- intend to be available for follow up in Molepolole, Gaborone or Mochudi for 18 months post-delivery
- have access to a cell phone (including phone of friend or relative)
Parent Doris Duke Study Exclusion Criteria Post-partum females excluded if
- did not attend antenatal care or were not included in Tsepamo surveillance
- maternal age <18,
- females who do not speak English or Setswana,
- unable or unwilling to give consent
- will not be able to attend follow up at a study site
- do not have access to any cell phone for follow up calls
Additional Inclusion Criteria for this PK Study
- For DMPA and ETG implant groups, intends to initiate or continue use of DMPA or ETG implant for at least another three or six months, respectively,
- For the CAB-LA groups, have received at least three consecutive CAB injections on time, including the one administered concurrently while starting a contraceptive method,
- Willing to undergo phlebotomy every 4 weeks for the duration of the sub-study period Additional Exclusion Criteria for this PK Study
1) Use or anticipated use of nicotine-containing products (e.g., cigarettes or hookahs) known to interact with CAB-LA for the duration of the sub-study period 2) Use within the previous 90 days, current use, or planned future concomitant use of other hormonal contraceptives, including oral contraceptive methods 3) BMI≥35 4) Has any of the following laboratory abnormalities within the last year:
- Serum ALT>5x ULN at the time of screening,
- Serum creatinine >2.5x ULN at the time of screening. 5) Has any other condition that, in the opinion of the sub-study PI/designee, would preclude informed consent, make study participation unsafe, or complicate interpretation of study outcome 6) HIV infected females on the Doris Duke parent study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Group 1: CAB-LA + IM DMPA
Injectable cabotegravir 600mg + intramuscular depo-medroxyprogesterone acetate 150mg (IM DMPA) |
Injectable cabotegravir 600 mg administered as long-acting HIV pre-exposure prophylaxis (PrEP). |
|
Group 2: CAB-LA + ETG implant
Injectable cabotegravir 600mg + etonogestrel (ETG) implant 68mg |
Injectable cabotegravir 600 mg administered as long-acting HIV pre-exposure prophylaxis (PrEP). |
|
Group 3: CAB-LA + no hormonal method
Injectable cabotegravir 600mg + no hormonal method |
Injectable cabotegravir 600 mg administered as long-acting HIV pre-exposure prophylaxis (PrEP). |
|
Group 4: No PrEP + IM DMPA
No PrEP + intramuscular depot medroxyprogesterone acetate (IM DMPA) 150mg |
No HIV pre-exposure prophylaxis administered |
|
Group 5: No PrEP + ETG implant
No PrEP + etonogestrel (ETG) implant 68mg |
No HIV pre-exposure prophylaxis administered |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To evaluate any associations between CAB-LA exposure and hormonal contraceptive use in the three groups of IM DMPA, ETG implant, and non-hormonal method users by generating geometric mean hormone concentrations (Aim 1a)
時間枠:0, 4, 8, 12 weeks for IM DMPA; 0, 4, 8, 12, 24 weeks for ETG implant and non-hormonal method users
|
Mean hormone concentrations starting at 0 week (when feasible), 4 weeks, 8 weeks, 12 weeks, and 24 weeks, as applicable to the three contraceptive groups, after contraceptive method initiation and at least after receiving 3rd dose of CAB-LA if in the CAB-LA groups. |
0, 4, 8, 12 weeks for IM DMPA; 0, 4, 8, 12, 24 weeks for ETG implant and non-hormonal method users
|
|
To evaluate any associations between hormonal contraceptive exposure and CAB-LA use by generating geometric mean trough CAB-LA concentrations measured immediately prior to dosing of next CAB-LA (Aim 1b)
時間枠:Immediately prior to each scheduled CAB-LA injection
|
Mean trough CAB-LA concentrations prior to next dosing of CAB-LA |
Immediately prior to each scheduled CAB-LA injection
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of adverse events associated with CAB-LA and hormonal contraceptive methods (Aim 2a1)
時間枠:12 and 24 weeks after contraceptive method initiation
|
Number and proportion of participants experiencing adverse events, graded using the Division of AIDS (DAIDS) Adverse Event Grading Table. |
12 and 24 weeks after contraceptive method initiation
|
|
Participant satisfaction with CAB-LA and hormonal contraceptive method measured by questionnaire (Aim 2a2)
時間枠:12 and 24 weeks after contraceptive method initiation
|
Participant-reported satisfaction scores assessed using a questionnaire. |
12 and 24 weeks after contraceptive method initiation
|
|
Continuation rates of CAB-LA and hormonal contraceptive method (Aim 2a3)
時間枠:12 and 24 weeks after contraceptive method initiation
|
Proportion of participants continuing use of CAB-LA and the contraceptive method at each time point. |
12 and 24 weeks after contraceptive method initiation
|
|
Participants' experiences and decision-making regarding CAB-LA and contraceptive method options assessed by semi-structured interviews (Aim 2b)
時間枠:At the end of study participation or up to 12 months after study participation
|
Qualitative assessment of participants' experiences, preferences, and decision-making processes regarding CAB-LA and contraceptive method use or switching, collected through semi-structured interviews conducted by trained study staff and audio-recorded, transcribed, and analyzed using thematic analysis. |
At the end of study participation or up to 12 months after study participation
|
協力者と研究者
協力者
捜査官
- 主任研究者:Rena Patel, MD, MPH, MPhil、University of Alabama at Birmingham
- 主任研究者:Rebecca Zash、Division of Infectious Disease Beth Israel Deaconess Medical Center
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- IRB-300013405
- R01AI155052 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。